A comprehensive overview of the relationship between RET gene and tumor occurrence

Article Oncology

Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

Alexander Drilon et al.

Summary: In this study, selpercatinib demonstrated durable and robust responses in both previously treated and treatment-naive patients with RET fusion-positive NSCLC, including intracranial activity.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing

Minke Shi et al.

Summary: The fusion patterns of RET in a large group of Chinese cancer patients were identified, with KIF5B, CCDC6, and ERC1 being the most common fusion partners. The study detected 17 novel fusions for the first time. Analysis showed a preference for fusion partners in different tumor types, which can guide clinicians in determining tumors suitable for RET targeted therapies.

CANCER SCIENCE (2022)

Add to Collection

Review Oncology

Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications

Daniel Kazdal et al.

Summary: Targeted therapy is preferred over chemotherapy and immunotherapy for actionable gene fusions in late-stage non-small cell lung carcinoma (NSCLC) due to its superior efficacy and tolerability. Testing for ALK, ROS1, NTRK, and RET gene fusions is now mandatory for all newly diagnosed advanced non-squamous NSCLC patients. RNA next-generation sequencing (NGS) or combined DNA/RNA NGS is the preferred method for detecting gene fusions. Recent advancements have led to the discovery of new gene fusions, necessitating the development of comprehensive detection methods and promising therapies.

GENES CHROMOSOMES & CANCER (2022)

Add to Collection

Article Oncology

Molecular targets of tyrosine kinase inhibitors in thyroid cancer

Poupak Fallahi et al.

Summary: Thyroid cancer is a common cancer with a rising incidence worldwide. Surgery is the primary treatment strategy, but some patients experience recurrence during follow-up. Resistance to radioactive iodine is a poor prognostic factor. Significant advances have been made in understanding the molecular pathways of thyroid cancer, leading to the development of tyrosine kinase inhibitors as new treatment options. However, further research is needed.

SEMINARS IN CANCER BIOLOGY (2022)

Add to Collection

Article Biology

Ret kinase-mediated mechanical induction of colon stem cells by tumor growth pressure stimulates cancer progression in vivo

Thanh Huong Nguyen Ho-Bouldoires et al.

Summary: The study found that high frequency pulsatile mechanical stresses maintain the physiological level of mice colon stem cells through the mechanosensitive Ret kinase. However, when stimulated by permanent tumor growth pressure, the stem cell levels increase pathologically and undergo hyperproliferation and tumorigenic transformation. Additionally, Ret activation in human colon cancer tissue is associated with tumor grade.

COMMUNICATIONS BIOLOGY (2022)

Add to Collection

Review Medicine, Research & Experimental

Contemporary Management of Thyroid Nodules

Kristen Kobaly et al.

Summary: Thyroid nodules are common, especially in women and older individuals. Ultrasonography is a standard technique for evaluating thyroid nodules, and risk stratification systems based on ultrasound appearance are used to determine the risk of malignancy. Cytology results and molecular testing can help further assess the need for surgery or observation.

ANNUAL REVIEW OF MEDICINE (2022)

Add to Collection

Editorial Material Oncology

Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib

David Chun Cheong Tsui et al.

Summary: This article reports a case of a patient with RET fusion-positive NSCLC who had leptomeningeal progression after using pralsetinib, but achieved a clinical and radiographic CNS response after switching to selpercatinib.

CLINICAL LUNG CANCER (2022)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

Recent Advances in Thyroid Cancer Research

Daniela Grimm

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Oncology

The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046

Matteo Repetto et al.

Summary: The study aims to predict potential mutations inducing resistance to TPX-0046, to overcome resistance to FDA approved RET inhibitors. The findings suggest that different mutations have different effects on TPX-0046 binding, which is important for the development of second and third generation RET inhibitors and clinical trial design.

INVESTIGATIONAL NEW DRUGS (2022)

Add to Collection

Review Multidisciplinary Sciences

RET receptor signaling: Function in development, metabolic disease, and cancer

Masahide Takahashi

Summary: The RET gene is associated with various cancers and developmental disorders, and its receptor plays crucial roles in the development of the nervous system, kidneys, urinary tract, and spermatogonial stem cells. Additionally, GDF15 and RET activation affect body weight, metabolism, and anorexia-cachexia syndrome.

PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2022)

Add to Collection

Article Multidisciplinary Sciences

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Ezra Y. Rosen et al.

Summary: The study has established the efficacy of the highly selective RET inhibitor selpercatinib in patients with RET-driven cancers, but also discovered potential mechanisms of resistance, revealing the complexity of acquired resistance and suggesting the importance of combination therapy targeting alternative pathways in overcoming resistance.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Endocrinology & Metabolism

The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020

Margherita Pizzato et al.

Summary: The incidence rates of thyroid cancer in 2020 were higher in high human development index countries compared to low and medium human development index countries. However, mortality rates were relatively similar across different settings. This suggests an overdiagnosis effect in many countries and confirms the relevance of thyroid cancer overdiagnosis as a global public health problem.

LANCET DIABETES & ENDOCRINOLOGY (2022)

Add to Collection

Review Oncology

New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2

Maria Eugenia Olmedo et al.

Summary: The discovery of gene mutations in EGFR and rearrangements in ALK in 2004 marked the beginning of a targeted therapy era for advanced non-small cell lung cancer. In addition to EGFR and ALK, other gene alterations such as ROS1 have been identified as potential therapeutic targets for a small subgroup of patients.

WORLD JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

F. Griesinger et al.

Summary: Treatment with Pralsetinib showed significant efficacy and good tolerability in treatment-naive patients. The intracranial response rate in patients with intracranial metastases was high, warranting further investigation.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Cancer treatment and survivorship statistics, 2022

Kimberly D. Miller et al.

Summary: The number of cancer survivors in the United States is increasing due to population growth, aging, and improved detection and treatment. The most prevalent cancers are prostate, skin melanoma, and colon and rectum for males, and breast, uterine corpus, and thyroid for females. Treatment disparities exist, with Black patients being less likely to be diagnosed with early-stage cancer and having lower surgical receipt rates.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Cell Biology

Integrated proteogenomic characterization of medullary thyroid carcinoma

Xiao Shi et al.

Summary: In this study, a comprehensive multi-omics analysis was conducted to characterize Medullary thyroid carcinoma (MTC). Novel driver genes and molecular subtypes were identified, and potential therapeutic targets and prognostic biomarkers were proposed. This study provides important insights into MTC biology and offers valuable resources for future investigations.

CELL DISCOVERY (2022)

Add to Collection

Article Pathology

Identification of fusions with potential clinical significance in melanoma

Jakob M. T. Moran et al.

Summary: Gene fusions, although rare in melanoma, may have therapeutic implications. A study detected 16 fusions in samples from 16 patients, with 75% of the fusions potentially targetable. Novel fusions and fusions reported in other malignancies but not in melanoma were identified. The detection of fusions may have a clinically significant impact in melanoma patients who have failed front-line immunotherapy.

MODERN PATHOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial

Vivek Subbiah et al.

Summary: Pralsetinib is a potent and selective inhibitor of RET receptor tyrosine kinase, showing promising efficacy in patients with diverse RET fusion-positive solid tumors. It demonstrates rapid, robust, and durable anti-tumor activity, regardless of tumor type or RET fusion partner.

NATURE MEDICINE (2022)

Add to Collection

Review Oncology

RET signaling pathway and RET inhibitors in human cancer

Angelina T. Regua et al.

Summary: Aberrant activation of RET receptor tyrosine kinase is associated with various types of cancer and poor prognosis. Inhibitors targeting RET kinase activity have shown promising preclinical and clinical efficacy in treating metastatic cancers.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Super-enhancer-controlled positive feedback loop BRD4/ERα-RET-ERα promotes ERα-positive breast cancer

Zao-zao Zheng et al.

Summary: This study uncovers the critical role of a super-enhancer-associated positive feedback loop constituting BRD4/ERα-RET-ERα in ERα-positive breast cancer and suggests that targeting components in this loop would provide a new therapeutic avenue for treating ERα-positive breast cancer in the clinic.

NUCLEIC ACIDS RESEARCH (2022)

Add to Collection

Review Oncology

Precision oncology for RET-related tumors

Antonella Verrienti et al.

Summary: Aberrant activation of the RET proto-oncogene is implicated in multiple cancers. Drugs that inhibit RET have shown good efficacy and tolerability, with the development of new RET selective inhibitors. The advent of high-throughput technology has identified tumors with RET deletions that may be targeted by RET inhibitors.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

Efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancers: results from the phase II LIBRETTO-321 study

Xiangqian Zheng et al.

Summary: Selpercatinib demonstrates robust antitumor activity and good tolerability in Chinese patients with advanced RET-altered TC.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection

Article Biology

Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage

Meghna Mehta et al.

Summary: The study demonstrated that Regorafenib enhanced radiosensitivity of breast cancer cells by inhibiting the expression of multiple receptor tyrosine kinases, VEGF-mediated angiogenesis, and DNA damage response in TNBC.

INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2021)

Add to Collection

Article Oncology

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Ezra Y. Rosen et al.

Summary: The RET proto-oncogene is activated by gene fusion in 1%-2% of NSCLC, while MET amplification is associated with resistance to selpercatinib. Combination therapy with selpercatinib and crizotinib can overcome MET-mediated resistance to RET inhibition.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Endocrinology & Metabolism

Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer

Viktoria F. Koehler et al.

Summary: The study evaluated the efficacy of vandetanib and cabozantinib in treating patients with medullary thyroid cancer outside of clinical trials at four German tertiary care centers. The findings suggest that both drugs are effective treatment options for the majority of patients with MTC.

THYROID (2021)

Add to Collection

Article Oncology

Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States

Lisa M. Hess et al.

Summary: The study revealed that patients with RET fusions have more favorable overall survival rates, but after adjusting for baseline covariates, there were no significant differences in either OS or PFS based on RET status among patients treated with standard therapy.

BMC CANCER (2021)

Add to Collection

Review Oncology

Diagnostics, therapeutics and RET inhibitor resistance for RET fusion?positive non-small cell lung cancers and future perspectives

Chang Lu et al.

Summary: This article summarizes the current hot topic of selective RET inhibitors and outlines the utility of various diagnostic techniques, as well as the management evidence for RET fusion-positive NSCLC patients, including specific patient groups and mechanisms of acquired resistance.

CANCER TREATMENT REVIEWS (2021)

Add to Collection

Article Oncology

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions

Diana Bradford et al.

Summary: The FDA granted accelerated approval to selpercatinib on May 8, 2020 for patients with metastatic RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. The approval was based on significant effects on overall response rate and prolonged duration of responses observed in clinical trials across multiple indications. The product label includes warnings for various adverse reactions such as hepatotoxicity, hypertension, and embryo-fetal toxicity.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

V Subbiah et al.

Summary: The study revealed that RET mutations resistant to selpercatinib and pralsetinib mainly located at the solvent front and hinge regions in medullary thyroid cancer and non-small-cell lung cancer. The unconventional binding mode of selpercatinib and pralsetinib to RET avoids interference from gatekeeper mutations but is susceptible to non-gatekeeper mutations.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Letter Oncology

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer

V. Subbiah et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Letter Oncology

A Novel Oncogenic RET Fusion Variant in NSCLC: RELCH-RET

Scott P. Myrand

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Nasser H. Hanna et al.

Summary: The updated guidelines provide evidence-based recommendations for systemic therapy in stage IV NSCLC patients with driver alterations, based on systematic reviews of randomized controlled trials and meeting abstracts. These recommendations emphasize the importance of testing for targetable mutations before initiating therapy, and highlight the use of targeted therapies for specific alterations like ROS-1 fusions and BRAF V600e mutations.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC

Weihua Li et al.

Summary: Variable genomic breakpoints of ALK, ROS1, and RET fusions in NSCLC can affect the efficacy of matched targeted therapy. Uncommon fusions may not reliably predict therapy response, and functional validation by RNA or protein assay can improve accurate detection and interpretation of rare fusions.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Review Endocrinology & Metabolism

The importance of the RET gene in thyroid cancer and therapeutic implications

Domenico Salvatore et al.

Summary: Alterations of RET kinase have been found in diverse thyroid cancer subtypes, including gene rearrangements and mutations. RET kinase inhibitors are an attractive therapeutic target for patients with RET alterations, showing promising results in the treatment of advanced thyroid cancer.

NATURE REVIEWS ENDOCRINOLOGY (2021)

Add to Collection

Review Oncology

Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives

Sara Fancelli et al.

Summary: This review discusses recent knowledge on RET resistance in NSCLC and the development of new drugs or drug combinations. While pralsetinib and selpercatinib are effective against NSCLC, there is a need for the next generation of TKIs to overcome adaptive mutations. Co-occurring amplifications of KRAS and MET may also present additional mechanisms of resistance to direct inhibition.

CANCERS (2021)

Add to Collection

Editorial Material Oncology

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA

C. M. Della Corte et al.

ESMO OPEN (2021)

Add to Collection

Article Oncology

Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer

Lori J. Wirth et al.

Summary: The study aimed to evaluate the efficacy of Lenvatinib in anaplastic thyroid cancer (ATC) and found that Lenvatinib monotherapy may not be an effective treatment for ATC, suggesting the need for further investigation.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Therapeutic strategies in RET gene rearranged non-small cell lung cancer

Leylah M. Drusbosky et al.

Summary: Recent FDA approvals for tumor-agnostic drugs have shifted cancer treatment from organ/histology-specific strategies to biomarker-guided approaches. RET gene fusions, known oncogenic drivers in various tumors, can be effectively targeted by inhibitors like selpercatinib and pralsetinib, showing significant clinical benefits in NSCLC patients.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Oncology

Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer

Kiyotaka Yoh et al.

Summary: The study on the efficacy and safety of vandetanib in previously treated RET-rearranged advanced NSCLC patients showed a prolonged PFS and OS, with hypertension, diarrhea, and rash acneiform being the most common adverse events.

LUNG CANCER (2021)

Add to Collection

Article Pharmacology & Pharmacy

Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling

Laura Schubert et al.

Summary: The study introduced three novel RET fusion-positive non-small cell lung cancer cell lines, demonstrating their differential responses to RET inhibition and regulation of downstream signaling, offering important insights into the regulation of response to RET tyrosine kinase inhibitors and other potential therapeutic targets.

MOLECULAR PHARMACOLOGY (2021)

Add to Collection

Article Cell Biology

Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model

Zi-Ning Lei et al.

Summary: The study demonstrates that CBZ can inhibit the ABCG2 transporter and resensitize drug-resistant cancer cells to specific drugs, showing promising reversal effects in an in vivo xenograft model.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Article Oncology

A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer

Philip M. Spanheimer et al.

Summary: In this study, preoperative vandetanib treatment for two weeks in patients with invasive breast cancer did not show significant differences in markers of proliferation and apoptosis compared to placebo. However, there was a trend towards reduction in p-ERK activation and enhanced effects in Ret-expressing tumors with vandetanib treatment, aligning with the investigational hypothesis.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2021)

Add to Collection

Article Oncology

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

Janice Kim et al.

Summary: The FDA granted accelerated approval for pralsetinib for non-small cell lung cancer and thyroid cancer, based on substantial overall response rates and durable responses in patients with RET-altered tumors. However, the product label includes warnings and precautions for various adverse events and risks.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Review Chemistry, Medicinal

Relevance of Aromatase Inhibitors in Breast Cancer Treatment

Ankita Sood et al.

Summary: Treatment for breast cancer remains challenging, with aromatase inhibitors showing significantly improved efficacy and safety compared to other drugs.

CURRENT TOPICS IN MEDICINAL CHEMISTRY (2021)

Add to Collection

Article Immunology

Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer

Naleen Raj Bhandari et al.

Summary: This study investigated outcomes of RET fusion-positive NSCLC patients receiving ICI-based treatments in the US, finding them consistent with unselected populations. Despite limitations in sample size, it provides insights into survival outcomes of this specific patient subgroup.

IMMUNOTHERAPY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Current and Future Development in Lung Cancer Diagnosis

Reem Nooreldeen et al.

Summary: Lung cancer is the leading cause of cancer-related deaths in North America and other developed countries, emphasizing the importance of early diagnosis. Current diagnostic methods have limitations and necessitate the search for new biomarkers to improve early detection rates.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Oncology

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Marcelo Negrao et al.

Summary: High TMB and PD-L1 expression are predictive for benefit from ICB treatment in oncogene-driven NSCLCs. NSCLC harboring BRAF mutations demonstrated superior benefit from ICB that may be attributed to higher TMB and higher PD-L1 expression in these tumors.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Review Oncology

Precision therapy for RET-altered cancers with RET inhibitors

Kyaw Z. Thein et al.

Summary: RET is involved in physiological development and its activated mutations are potent drivers of cancer. Traditional treatment with MKIs has modest efficacy but notable toxicities. Novel RET inhibitors like selpercatinib and pralsetinib have shown success in the clinic, providing a promising future outlook.

TRENDS IN CANCER (2021)

Add to Collection

Article Pharmacology & Pharmacy

Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions

H. Zheng et al.

Summary: Aberrations in the oncogene RET have been implicated in various malignancies, such as lung and thyroid cancers. Targeted therapy using MKIs has shown limited efficacy due to off-target toxicity. The FDA approved a novel specific RET inhibitor, selpercatinib, in May 2020 for certain subtypes of lung and thyroid cancers with RET alterations, highlighting the importance of precision medicine in cancer therapy.

DRUGS OF TODAY (2021)

Add to Collection

Article Oncology

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Oliver Illini et al.

Summary: In a real-world setting, the selective RET-inhibitor selpercatinib demonstrated durable systemic and intracranial antitumor activity in RET fusion-positive NSCLC patients and was well tolerated.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)

Add to Collection

Article Endocrinology & Metabolism

A monoclonal antibody raised against a synthetic oxytocin peptide stains mouse hypothalamic neurones

Yuji Kogami et al.

JOURNAL OF NEUROENDOCRINOLOGY (2020)

Add to Collection

Article Oncology

State-of-the-Art Strategies for Targeting RET-Dependent Cancers

Vivek Subbiah et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Ret Receptor Has Distinct Alterations and Functions in Breast Cancer

Albana Gattelli et al.

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2020)

Add to Collection

Article Oncology

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018

Florian Guisier et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Oncology

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

Benjamin J. Solomon et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Review Genetics & Heredity

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues

Massimo Santoro et al.

GENES (2020)

Add to Collection

Editorial Material Oncology

Defining resistance mechanisms to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

L. Tan et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Letter Oncology

Identification of a Novel KIF5B-RET, ABHD17C-RET Double-Fusion Variant in Lung Adenocarcinoma and Response to Cabozantinib

Qiufan Zheng et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Review Cell Biology

GDNF/RET signaling in dopamine neurons in vivo

James A. Conway et al.

CELL AND TISSUE RESEARCH (2020)

Add to Collection

Article Biochemistry & Molecular Biology

RET isoforms contribute differentially to invasive processes in pancreatic ductal adenocarcinoma

Eric Y. Lian et al.

ONCOGENE (2020)

Add to Collection

Review Oncology

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

Zhichao Tian et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Oncology

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies

Aparna Hegde et al.

ESMO OPEN (2020)

Add to Collection

Review Physiology

Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review

Kengo Takeuchi

FRONTIERS IN PHYSIOLOGY (2019)

Add to Collection

Article Oncology

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro

Toshio Fujino et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection

Article Biotechnology & Applied Microbiology

KIFSB-RET fusion gene and its correlation with clinicopathological and prognostic features in lung cancer: a meta-analysis

Xiao-Feng Cong et al.

ONCOTARGETS AND THERAPY (2019)

Add to Collection

Article Oncology

A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma

Toyoaki Hida et al.

LUNG CANCER (2019)

Add to Collection

Article Oncology

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

S. Filetti et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Review Oncology

RET fusions in solid tumors

Andrew Y. Li et al.

CANCER TREATMENT REVIEWS (2019)

Add to Collection

Article Oncology

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Martin Reck et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers

Michael Offin et al.

JCO PRECISION ONCOLOGY (2019)

Add to Collection

Review Oncology

RET in breast cancer: pathogenic implications and mechanisms of drug resistance

Cristiana Lo Nigro et al.

CANCER DRUG RESISTANCE (2019)

Add to Collection

Article Oncology

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers

Alexander Drilon et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

Add to Collection

Article Oncology

Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)

Elizabeth Dudnik et al.

LUNG CANCER (2018)

Add to Collection

Article Oncology

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion

Zofia Piotrowska et al.

CANCER DISCOVERY (2018)

Add to Collection

Article Multidisciplinary Sciences

RET rearrangements are actionable alterations in breast cancer

Bhavna S. Paratala et al.

NATURE COMMUNICATIONS (2018)

Add to Collection

Article Oncology

Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases

Samuel J. Klempner et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

Add to Collection

Article Oncology

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers

A. Drilon et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Article Oncology

Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer

Atsushi Horiike et al.

LUNG CANCER (2016)

Add to Collection

Article Oncology

Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts

Elena Andreucci et al.

ONCOTARGET (2016)

Add to Collection

Article Oncology

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

Kiyoshi Okamoto et al.

CANCER LETTERS (2013)

Add to Collection

A comprehensive overview of the relationship between RET gene and tumor occurrence

Related references

Export Citation

Share Paper